Previsão

Não temos dados de analistas para esta empresa.

Notícias Ir para o feed de notícias

Ambu share falls 15% after slightly missed quarter

Ambu narrowly missed consensus expectations in the third quarter with EPS of $0.62 and revenue of $1.64bn, after which the stock fell 15.15% to $66.35. Organic revenue growth was 10.3%, driven by Endoscopy Solutions (+16%), and reported EBIT rose to 13.5%. Management raised the full-year forecast for organic growth to around 10% but warned of short-term margin pressures from higher selling expenses, currency and duties costs, and upcoming duty refunds that are expected to support the next quarter. » Mais em de.investing.com
Ambu forecasts significant quarterly growth in EPS and revenue

Ambu will publish results on 26 August 2026 for the quarter ended 30 June 2026. Analysts on average expect EPS of 0.617 DKK, up 34.13% from 0.460 DKK a year earlier, and revenue of 1.65 billion DKK on average (+9.43% versus 1.51 billion DKK). For the current fiscal year, consensus estimates are 2.32 DKK earnings per share (previous year 2.29 DKK) and annual revenue of 6.47 billion DKK (previous year 6.04 billion DKK). » Mais em finanzen.net
Ambu confirms outlook after Q1 – endoscopy growth offsets currency and tariff headwinds

Ambu reported organic revenue growth of 8.6% in Q1 2025/26 (reported 3.2% after currency impact) and total revenue of DKK 1,558m. The driver was the Endoscopy Solutions segment with 14.4% organic growth; Anesthesia & Patient Monitoring was flat. EBIT margin before special items fell to 10.5%; adjusted for tariffs and currency effects it would be 15.2%. Free cash flow was DKK 13m. Ambu confirmed its full-year outlook of 10–13% organic revenue growth and a target EBIT margin of 12–14%, but continued to see currency and tariff risks. » Mais em de.investing.com

Dividendos históricos Dividendos

Todos os indicadores de dividendos Todos os indicadores

Em 2025, Ambu já distribuiu € 0,0549 em dividendos. A última distribuição ocorreu em dezembro de 2025.

Dados financeiros da empresa

No último trimestre, Ambu registou receitas de € 218,63 mi e um ganho líquido de € 20,8 mi

(EUR)	junho de 2026	YoY
Receitas	218,63 mi	8,24%
Ganho bruto	129,98 mi	9,33%
Ganho líquido	20,8 mi	26,14%
EBITDA	42,79 mi	20,02%

Dados fundamentais

Métrica	Valor
Capitalização bolsista	€ 2,27 bi
Número de ações	263,04 mi
Máximo/mínimo de 52 semanas	€ 13,29 - € 8,11
Rentabilidade de dividendos	0,62%
Dividendos TTM	€ 0,0549
Beta	1,31
PER (PE Ratio)	34,63
PEG (PEG Ratio)	0,81
P/VC (PB Ratio)	2,86
P/V (PS Ratio)	2,82

Perfil da empresa

Ambu A/S entwickelt, produziert und vertreibt medizinische Geräte für Krankenhäuser, Kliniken und Rettungsdienste weltweit. Das Unternehmen bietet Gesundheitslösungen in den Bereichen Visualisierung, Anästhesie, Patientenüberwachung und Diagnostik. Das Unternehmen bietet Produkte für die Endoskopie, wie Bronchoskope und Monitore, und Produkte für die Neurologie, wie EEG- und EMG-Elektroden, EMG-geführte Injektionen und intraoperative Überwachungsprodukte. Darüber hinaus bietet das Unternehmen Produkte für die Kardiologie, bestehend aus EKG-Elektroden, sowie Produkte für das Atemwegsmanagement und die Anästhesie, wie Bronchoskope, Videolaryngoskope, doppel- und einlumige Tuben, endobronchiale Blocker, Kehlkopf- und Gesichtsmasken, Beatmungsbeutel und Wiederbelebungsgeräte. Darüber hinaus bietet das Unternehmen Befreiungsmanschetten, Kopf-Immobilizer, CPR-Atembarrieren und Übungspuppen an. Ambu A/S wurde 1937 gegründet und hat seinen Hauptsitz in Ballerup, Dänemark.

Nome	Ambu
CEO	Britt Meelby Jensen
Sede	Ballerup, cr Dinamarca
Site	ambu.com
Setor	Cuidados de saúde
Indústria	Cuidados de saúde: equipamentos e produtos
Entrada em bolsa	11/02/2004
Colaboradores	5.384